VETERINARY ONCOLOGY MARKET ANALYSIS

Veterinary Oncology Market, By Animal Type (Companion Animal (Equine, Canine, and Feline) and Livestock Animal), By Therapy Type (Chemotherapy, Combination Therapy, Immunotherapy, and Targeted Therapy), By Mode of Administration (Oral and Intravenous), By Application (Canine Lymphoma, Osteosarcoma (OSA), Mast Cell Cancer, Melanoma, and Others), By Distribution Channel (Hospital Pharmacies, Government Agencies, and Retail Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : May 2024
Code : CMI2995
Pages :225
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenge – Stringent Regulations for Veterinary Vaccines

Stringent regulations for veterinary vaccines across various geographies are proving to be a major restraining factor for the growth of the global veterinary oncology market. Regulatory authorities across countries have implemented strict norms and guidelines for the development, manufacturing and approval of new veterinary vaccines to ensure safety, efficacy, and quality. Complying with these complex regulations involves extensive clinical trials, comprehensive documentation and significant investments of both time and funds. This lengthens the overall product development lifecycle considerably and delays the market introduction of new oncology vaccines.

Market Opportunity – Increasing Investments for Veterinary Oncology

Increasing investments for veterinary oncology healthcare is expected to offer lucrative opportunities in the market. For instance, in December 2021, PetDx, the startup behind an early cancer-detecting blood test for dogs, raised the funding of USD 62 million to get canine cancer-detecting tech to vets across the U.S. OncoK9 can detect 30 cancers from a blood draw in front of more veterinarians and become a standard test in pet clinics across the country.